查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511910

抗糖尿病藥物市場規模、佔有率和趨勢分析報告：按藥物類別、類型、給藥途徑、分銷管道、地區和細分市場預測，2024-2030年

Antidiabetics Market Size, Share & Trends Analysis Report By Drug Class (GLP-1 Receptor Agonists, Insulin), By Type (Type 1, Type 2), By Route of Administration (Oral, Intravenous), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

抗糖尿病藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2023年至2030年全球抗糖尿病藥物市場規模將以12.23%的複合年成長率成長，2030年將達到1844.7億美元。

糖尿病盛行率的增加是該市場的主要促進因素。不規則的飲食習慣和日益增加的肥胖預計也會透過誘發目標疾病的發生率來推動產品需求。目前正在研發的產品的未來商業化以及亞太和拉丁美洲新興市場存在的重大開拓機會預計將在未來幾年推動市場成長。

胰島素是盈利最高的細分市場，2013年市場規模超過200億美元。胰島素也是這個市場上最賺錢的細分市場之一。推出具有更高功效的新產品以及存在有利的政府舉措是增加市場吸引力的因素。

抗糖尿病藥物市場報告亮點

  • 新核准的DPP-4 抑制劑，如 Januvia、Nesina 和 Onglyza，因其每日一次的給藥方案和安全性而迅速滲透到市場。
  • 北美是最成熟的抗糖尿病藥物市場，2023年佔市場佔有率為41.51%。的市場成長。
  • 預計亞太地區將為製造商提供有利的未來成長機會。大量未滿足的需求和快速改善的醫療基礎設施是預計推動該地區市場成長的因素之一。當地製造商推出廉價產品也預計將推動市場發展。
  • 抗糖尿病藥物的主要市場參與者包括阿斯特捷利康公司、拜耳公司、工業公司、勃林格殷格翰公司、百時美施貴寶公司、默克公司、強生服務公司、輝瑞公司。
  • 該市場本質上是寡占，少數公司控制著70%以上的市場。對新產品開發的廣泛研發投資以及透過政府合約進入新興市場是這些公司採取的關鍵永續性策略。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢及展望
  • 市場動態
    • 糖尿病發生率上升
    • 研究和技術進步
    • 提高認知和早期療育
  • 市場限制因素分析
    • 開發成本高
    • 副作用和安全問題
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 藥品類別業務分析

  • 降血糖藥市場：藥品類別波動分析
  • 胰島素
  • GLP-1受體促效劑
  • DPP-4抑制劑
  • SGLT2抑制劑
  • DPP-4抑制劑
  • 其他

第5章依糖尿病類型分類的業務分析

  • 抗糖尿病藥物市場：依糖尿病類型波動分析
  • 類型1
  • 2型

第6章依途徑進行的業務分析

  • 抗糖尿病藥物市場：給藥途徑變化分析
  • 口服
  • 皮下的
  • 靜脈

第7章 通路業務分析

  • 抗糖尿病藥物市場：通路波動分析
  • 網路藥房
  • 醫院藥房
  • 零售藥房

第8章區域業務分析

  • 2022年及2030年按地區分類的抗糖尿病藥物市場佔有率
  • 北美洲
    • SWOT分析
    • 北美抗糖尿病藥物市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • SWOT分析
    • 歐洲抗糖尿病藥物市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • SWOT分析
    • 亞太地區抗糖尿病藥物市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • SWOT分析
    • 拉丁美洲抗糖尿病藥物市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • SWOT分析
    • 2018-2030年中東及非洲抗糖尿病藥物市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司分類
  • 策略規劃
  • 2022 年企業市場佔有率分析
  • 公司簡介/上市公司
    • AstraZeneca plc
    • Bayer AG
    • Takeda Pharmaceutical Company Limited
    • Eli Lilly and Company
    • Boehringer Ingelheim
    • Bristol-Myers Squibb Company
    • Pfizer, Inc.
    • Johnson &Johnson Services Inc.
    • Merck &Co. Inc
    • Novartis AG
Product Code: 978-1-68038-304-1

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 184.47 billion by 2030, expanding at a CAGR of 12.23% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2023 accounting for over 41.51% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Drug Class Segment
      • 1.1.1.2. Diabetes Type Segment
      • 1.1.1.3. Distribution Channel Segment
      • 1.1.1.4. Route of Administration Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising Diabetes Prevalence
    • 3.4.2. Advancements in Research and Technology
    • 3.4.3. Increasing Awareness and Early Intervention
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Development Costs
    • 3.5.2. Side Effects and Safety Concerns
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Drug Class Business Analysis

  • 4.1. Antidiabetics Market: Drug Class Movement Analysis
  • 4.2. Insulin
    • 4.2.1. Insulin Market, 2018 - 2030 (USD Million)
      • 4.2.1.1. Insulin Market, By Type
      • 4.2.1.1.1. Long-acting insulin
      • 4.2.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.2. Premix insulin
      • 4.2.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.3. Fast-acting insulin
      • 4.2.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
      • 4.2.1.1.4. Human insulin
      • 4.2.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
  • 4.3. GLP-1 Receptor Agonists
    • 4.3.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
  • 4.4. DPP- 4 Inhibitors
    • 4.4.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. SGLT2 Inhibitors
    • 4.5.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. DPP-4 Inhibitors
    • 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Type Business Analysis

  • 5.1. Antidiabetics Market: Diabetes Type Class Movement Analysis
  • 5.2. Type 1
    • 5.2.1. Type 1 Market, 2018 - 2030 (USD Million)
  • 5.3. Type 2
    • 5.3.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. Antidiabetics Market: Route of Administration Movement Analysis
  • 6.2. Oral
    • 6.2.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.3. Subcutaneous
    • 6.3.1. Subcutaneous Market, 2018 - 2030 (USD Million)
  • 6.4. Intravenous
    • 6.4.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. Antidiabetics Market: Distribution Channel Movement Analysis
  • 7.2. Online Pharmacies
    • 7.2.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Antidiabetics Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. U.S. Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Canada Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. UK Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Germany Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. France Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Italy Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Spain Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Denmark Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.9. Sweden
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Sweden Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.3.10. Norway
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Norway Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Japan Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. China Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. India Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Australia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Thailand Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.4.8. South Korea
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. South Korea Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Brazil Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Mexico Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.5.5. Argentina
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Competitive Scenario
      • 8.5.5.4. Regulatory Framework
      • 8.5.5.5. Argentina Antidiabetics Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. SWOT Analysis
    • 8.6.2. MEA Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. South Africa Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Saudi Arabia Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. UAE Antidiabetics Market, 2018 - 2030 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Kuwait Antidiabetics Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Company Profiles/Listing
    • 9.4.1. AstraZeneca plc
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Bayer AG
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Takeda Pharmaceutical Company Limited
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Boehringer Ingelheim
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Bristol-Myers Squibb Company
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Pfizer, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Johnson & Johnson Services Inc.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Merck & Co. Inc
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Novartis AG
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antidiabetics market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 Global antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 4 Global antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 Global antidiabetics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 North America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 10 North America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 North America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 U.S. antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 14 U.S. antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 U.S. antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Canda antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 18 Canada antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Canada antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Europe antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 23 Europe antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Europe antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 UK antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 UK antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 27 UK antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Germany antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 31 Germany antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 34 France antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 35 France antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Italy antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Italy antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 39 Italy antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Italy antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Spain antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 42 Spain antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 43 Spain antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Spain antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Denmark antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 47 Denmark antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Sweden antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 51 Sweden antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Norway antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 55 Norway antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Japan antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Japan antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 64 Japan antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Japan antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 China antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 China antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 68 China antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 China antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 India antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 71 India antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 72 India antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 India antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 Australia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 75 Australia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 76 Australia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 Australia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Thailand antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 79 Thailand antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 80 Thailand antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Thailand antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 South Korea antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 84 South Korea antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 South Korea antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 87 Latin America antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 88 Latin America antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 89 Latin America antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 92 Brazil antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 93 Brazil antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Mexico antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 96 Mexico antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 97 Mexico antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Mexico antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 100 Argentina antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 101 Argentina antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 Argentina antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa antidiabetics market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 109 South Africa antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 110 South Africa antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 South Africa antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 117 UAE antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 118 UAE antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 UAE antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait antidiabetics market, by drug type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait antidiabetics market, by diabetes type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait antidiabetics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 123 Kuwait antidiabetics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Antidiabetics market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global antidiabetics market: drug class movement analysis
  • Fig. 16 Global antidiabetics market, for Insulin, 2018 - 2030 (USD Million)
  • Fig. 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018 - 2030 (USD Million)
  • Fig. 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 19 Global antidiabetics market, for SGLT2 inhibitors, 2018 - 2030 (USD Million)
  • Fig. 20 Global antidiabetics market, for others, 2018 - 2030 (USD Million)
  • Fig. 21 Global antidiabetics market: diabetes type movement analysis
  • Fig. 22 Global antidiabetics market, for type 1, 2018 - 2030 (USD Million)
  • Fig. 23 Global antidiabetics market, for type 2, 2018 - 2030 (USD Million)
  • Fig. 24 Global antidiabetics market: route of administration movement analysis
  • Fig. 25 Global antidiabetics market, for oral, 2018 - 2030 (USD Million)
  • Fig. 26 Global antidiabetics market, for subcutaneous, 2018 - 2030 (USD Million)
  • Fig. 27 Global antidiabetics market, for intravenous, 2018 - 2030 (USD Million)
  • Fig. 28 Global antidiabetics market: distribution channel movement analysis
  • Fig. 29 Global antidiabetics market, for online pharmacies, 2018 - 2030 (USD Million)
  • Fig. 30 Global antidiabetics market, for hospital pharmacies, 2018 - 2030 (USD Million)
  • Fig. 31 Global antidiabetics market, retail pharmacies, 2018 - 2030 (USD Million)
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional outlook, 2022 & 2030
  • Fig. 34 Global antidiabetics market: region movement analysis
  • Fig. 35 North America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 40 UK antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 41 France antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 43 Spain antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 49 China antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 50 India antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 51 Australia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 61 UAE antidiabetics market, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait antidiabetics market, 2018 - 2030 (USD Million)